Infinitopes Granted Phase I/ IIa Clinical Trial Application Approval to Evaluate Precision Vaccine Targeting Early-Stage Oesophageal Cancer

Infinitopes United Kingdom

Revolutionary 'off-the-shelf' cancer vaccine designed to prevent the recurrence of oesophageal cancerITOP1 to enter first-in-human Phase I/IIa clinical development in the VISTA study in H1 2025Multicentre study to be conducted at four university cancer centres, aiming to raise the standard of care by reducing the recurrence of metastases and cancer-related deathsView original content:https://www.prnewswire.co.uk/news-releases/infinitopes-granted-phase-iiia-clinical-trial-application-approval-to-evaluate-precision-vaccine-targeting-early-stage-oesophageal-cancer-302423645.html